1997–2017年依替米星研究的文献计量分析

Bibliometric analysis on research of etimicin from 1997 to 2017

目的:对依替米星临床研究的相关文献进行统计分析,为临床合理用药提供参考。方法:利用文献计量学的方法,汇总依替米星临床研究的相关文献,对纳入文献的年份分布、语种、发表期刊、文献类型、临床感染类型、配伍禁忌、不良反应等进行统计分析。结果:共纳入相关文献527篇,相关研究以国内研究为主,且主要发表在中文期刊(374种,98.9%)。依替米星用于临床感染类型研究最多的是呼吸系统感染(86篇,57.7%);不良反应主要集中在耳毒性及肾毒性(38篇,52.1%);与头孢菌素类药物的配伍禁忌报道较多(38篇,40.4%)。结论:作为我国自主研制的氨基糖苷类抗生素,依替米星在临床应用范围广,不良反应较同类品种发生率低,对其更为深入的研究和探讨对于感染性疾病的防治具有重要意义。

Objective： To analyze the literature related to the clinical research of etimicin at the time of etimicin listed in China for 20 years, so as to provide references for clinical rational drug use. Methods： Based on the methods of bibliometrics, the relevant literature on the clinical research of etimicin were collected and summarized. Statistical analysis was carried out in terms of the publication date, languages, journals, types of literature, types of clinical infection, adverse reactions and incompatibility. Results： A total of 527 literature were included. The domestic research was dominant among the related literature, most of which were published in Chinese journals （374 journals, 98.9%）. Clinical research of etimicin mainly focused on respiratory infection （86 studies, 57.7%）. ADR research of etimicin mainly focused on ototoxicity and nephrotoxicity （38 studies, 52.1%）, and the incompatibility of etimicin with cephalosporins was reported in 38 articles, which accounted for 40.4% among enrolled studies. Conclusion： As a self-developed aminoglycoside antibiotic in China, etimicin had a wide range of clinical applications and a lower incidence of adverse reactions than similar varieties. It is of great signifcance to further study and explore etimicin for the prevention and treatment of infectious diseases.